Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

A Study of Dengue Vaccine in Healthy Toddlers Aged 12 to 15 Months in the Philippines

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Sanofi
ClinicalTrials.gov Identifier:
NCT01064141
First received: February 5, 2010
Last updated: February 5, 2013
Last verified: February 2013

February 5, 2010
February 5, 2013
January 2010
September 2012   (final data collection date for primary outcome measure)
To provide information concerning the safety in terms of solicited and unsolicited adverse events after primary administration of CYD Dengue vaccine. [ Time Frame: 28 days after each Dengue vaccination and entire study duration ] [ Designated as safety issue: Yes ]
Same as current
Complete list of historical versions of study NCT01064141 on ClinicalTrials.gov Archive Site
  • To provide information concerning the immunogenicity of CYD Dengue vaccine after each dose of primary vaccination. [ Time Frame: Day 28 after each Dengue vaccination ] [ Designated as safety issue: No ]
  • To provide information concerning the immunogenicity of childhood vaccines after primary vaccination. [ Time Frame: Day 28 after post-vaccination ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
A Study of Dengue Vaccine in Healthy Toddlers Aged 12 to 15 Months in the Philippines
Immunogenicity and Safety of CYD Dengue Vaccine in Healthy Toddlers Aged 12 to 15 Months in the Philippines

The purpose of this study is to investigate the potential for co-administration of the first dose of CYD Dengue vaccine with childhood vaccination.

Primary Objectives:

  • To describe the safety of CYD Dengue vaccine after each dose; first dose given alone or coadministered with childhood vaccines.

Secondary Objectives:

  • To describe the immunogenicity of CYD Dengue vaccine after each dose; first dose given alone or co-administered with childhood vaccines.

Participants will be enrolled in a 3-step enrollment and randomized to 1 of 4 treatment groups. Groups 1 and 2 will receive 5 vaccinations, and Groups 3 and 4 will received 6 vaccinations (childhood vaccines or placebo co-administered with the first dose of CYD Dengue vaccine in 2 separate arms). All toddlers will receive a pentavalent acellular pertussis combination vaccine or Combo (PENTAXIM®), planned approximately 10 months after enrollment.

Interventional
Phase 2
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
  • Dengue Fever
  • Dengue Hemorrhagic Fever
  • Biological: Live, attenuated, recombinant dengue serotypes 1, 2, 3 and 4 virus
    0.5 mL, Subcutaneous
    Other Name: CYD Dengue Vaccine
  • Biological: OKAVAX®:Attenuated live varicella-zoster virus and AVAXIM® 80U: Hepatitis A virus Vaccines
    0.5 mL, Subcutaneous and 0.5 mL, Intravascular
    Other Names:
    • OKAVAX®
    • AVAXIM® 80U
  • Biological: Live, attenuated, recombinant dengue serotypes 1, 2, 3 and 4 virus and Childhood vaccines
    0.5 mL, Subcutaneous and 0.5 mL, Subcutaneous
    Other Names:
    • CYD Dengue Vaccine
    • TRIMOVAX®
  • Biological: Live, attenuated, recombinant dengue serotypes 1, 2, 3 and 4 virus and NaCl (Placebo)
    0.5 mL Subcutaneous and 0.5 mL Subcutaneous
    Other Names:
    • CYD Dengue Vaccine
    • NaCl 0.9% (Placebo)
  • Experimental: Group 1: Dengue Vaccine Group
    Participants will receive CYD Dengue vaccine as Visits 1 and 2.
    Intervention: Biological: Live, attenuated, recombinant dengue serotypes 1, 2, 3 and 4 virus
  • Active Comparator: Group 2: Control Group
    Participants will receive Control Vaccines. (Varicella at Visit 1 and Hepatitis A at Visit 2)
    Intervention: Biological: OKAVAX®:Attenuated live varicella-zoster virus and AVAXIM® 80U: Hepatitis A virus Vaccines
  • Experimental: Group 3: Co-administration Group
    Participants will receive CYD Dengue vaccine and childhood vaccines at Visit 1 and CYD Dengue vaccine at Visit 2.
    Intervention: Biological: Live, attenuated, recombinant dengue serotypes 1, 2, 3 and 4 virus and Childhood vaccines
  • Experimental: Group 4: Sequential Administration Group
    Participants will receive CYD Dengue vaccine and a Placebo vaccine at Visit 1 and CYD Dengue vaccine at Visit 2.
    Intervention: Biological: Live, attenuated, recombinant dengue serotypes 1, 2, 3 and 4 virus and NaCl (Placebo)
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
210
November 2012
September 2012   (final data collection date for primary outcome measure)

Inclusion Criteria :

  • Toddler in good health based on medical history and medical examination
  • Toddler aged 12 to 15 months on the day of inclusion
  • Born at full term of pregnancy (≥ 37 weeks) and with a birth weight ≥ 2.5 kg
  • Provision of informed consent form signed by the parent(s) or other legally acceptable representative (and by an independent witness if required by local regulations)
  • Participant and parent/delegate able to attend all scheduled visits and comply with all trial procedures
  • Completion of previous vaccination program according to the national immunization schedule, except for measles

Exclusion Criteria :

  • Family members from the Investigator or from the staff involved in the trial
  • Chronic illness that, in the opinion of the investigator, is at a stage where it might interfere with trial conduct or completion
  • Known or suspected congenital or acquired immunodeficiency; or receipt of immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy within the preceding 6 months, or long-term systemic corticosteroids therapy (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months)
  • History of central nervous system disorder or disease, including seizures
  • History of varicella, measles, mumps, rubella and hepatitis A; confirmed either clinically, serologically, or microbiologically
  • Thrombocytopenia, bleeding disorder or anticoagulants in the 3 weeks preceding inclusion
  • Previous vaccination against measles-mumps-rubella, hepatitis A or varicella
  • Previous vaccination against flavivirus diseases
  • Known systemic hypersensitivity to any of the components of the vaccines, or history of a life-threatening reaction to the vaccines used in the trial or to a vaccine containing any of the same substances
  • Planned participation in another clinical trial during the present trial period
  • Participation in another clinical trial investigating a vaccine, drug, medical device, or medical procedure in the 4 weeks preceding the first trial vaccination
  • Receipt of blood or blood-derived products in the past 3 months, which might interfere with assessment of the immune response
  • Planned receipt of any vaccine in the 4 weeks following the first trial vaccination
  • Human immunodeficiency virus (HIV) seropositivity in the blood sample taken at screening
  • Clinically significant laboratory abnormalities, as judged by the Investigator, in blood sample taken at screening

Temporary exclusions: vaccination postponed until the condition is resolved:

  • Febrile illness (temperature ≥ 38°C) or moderate or severe acute illness/infection on the day of vaccination, according to Investigator judgment
  • Receipt of oral or injected antibiotic therapy within 72 hours prior to the vaccination visit
  • Any vaccination received in the 4 weeks preceding vaccination
Both
12 Months to 15 Months
Yes
Contact information is only displayed when the study is recruiting subjects
Philippines
 
NCT01064141
CYD08, UTN: U1111-1111-5855
Yes
Sanofi
Sanofi
Not Provided
Study Director: Medical Director Sanofi Pasteur Inc.
Sanofi
February 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP